Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer

Journal of Gene Medicine

Volumn 8, Issue 8, 2006, Pages 990-997

  Ogura, Tsuyoshi ^a,b   Mizukami, Hiroaki ^a   Mimuro, Jun ^a   Madoiwa, Seiji ^a   Okada, Takashi ^a   Matsushita, Takashi ^a   Urabe, Masashi ^a   Kume, Akihiro ^a   Hamada, Hiromi ^b   Yoshikawa, Hiroyuki ^b   Sakata, Yoichi ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

AAV vector; Coagulation factor IX; Luciferase; Neonatal gene therapy

Indexed keywords

BETA GALACTOSIDASE; BLOOD CLOTTING FACTOR 9; LUCIFERASE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; IMAGE ANALYSIS; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; NEWBORN; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; SEROTYPE; SEX DIFFERENCE; STAINING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANIMALS, NEWBORN; CYTOMEGALOVIRUS; DEPENDOVIRUS; EVALUATION STUDIES; FACTOR IX; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LAC OPERON; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; PLASMIDS; SEROTYPING; SEX FACTORS; TIME FACTORS; TISSUE DISTRIBUTION; TRANSGENES;

ADENO-ASSOCIATED VIRUS;

EID: 33747851472     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.916     Document Type: Article

References (28)

1. Chao H, Samulski R, Bellinger D, et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 1999; 6: 1695-1704.
2. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
3. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-2676.
4. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64-70.
5. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
6. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
7. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004; 103: 85-92.
8. Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-623.
9. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 2001; 4: 217-222.
10. Mingozzi F, Schuettrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002; 76: 10 497-10 502.
11. Coutelle C, Themis M, Waddington S, et al. The hopes and fears of in utero gene therapy for genetic disease - a review. Placenta 2003; 24(Suppl B): S114-121.
12. Mitchell M, Jerebtsova M, Batshaw ML, Newman K, Ye X. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther 2000; 7: 1986-1992.
13. Themis M, Schneider H, Kiserud T, et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther 1999; 6: 1239-1248.
14. Waddington SN, Buckley SM, Nivsarkar M, et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 2003; 101: 1359-1366.
15. Zhang J, Xu L, Haskins ME, Parker Ponder K. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs. Blood 2004; 103: 143-151.
16. Schneider H, Muhle C, Douar AM, et al. Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46-53.
17. Lipshutz GS, Titre D, Brindle M, et al. Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero. Mol Ther 2003; 8: 90-98.
18. Mochizuki S, Mizukami H, Kume A, et al. Adeno-associated virus (AAV) vector-mediated liver- and muscle-directed transgene expression using various kinds of promoters and serotypes. Gene Ther Mol Biol 2004; 8: 9-18.
19. Mochizuki S, Mizukami H, Ogura T, et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 2004; 11: 1081-1086.
20. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 5804-5809.
21. Mimuro J, Mizukami H, Ono F, et al. Specific detection of human coagulation factor IX in cynomolgus macaques. J Thromb Haemost 2004; 2: 275-280.
22. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-945.
23. Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-2419.
24. Kanazawa T, Mizukami H, Okada T, et al. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003; 10: 51-58.
25. Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003; 102: 480-488.
26. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in vivo transduction by recombinant adeno- associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
27. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003; 9: 1306-1312.
28. Louis M-H, Dutoit S, Denoux Y, et al. Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice. Cancer Gene Ther 2006; 13: 367-374.